In the original article, we neglected to include the funder the Excellent Youth Foundation of Jiangsu Province, China, BK20140032 to Rui Wang.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
gene-targeted oncolytic viral therapy, adenovirus, HCC, immunotherapy, virus engineering
Citation
Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R and Chu X (2020) Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front. Oncol. 10:701. doi: 10.3389/fonc.2020.00701
Received
13 April 2020
Accepted
15 April 2020
Published
05 May 2020
Volume
10 - 2020
Edited and reviewed by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Updates
Copyright
© 2020 Abudoureyimu, Lai, Tian, Wang, Wang and Chu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rui Wang wangrui218@163.com
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.